PURLs

Consider this strategy for upper GI bleeds

Author and Disclosure Information

 

References

WHAT'S NEW: Many reasons to limit transfusions for acute upper GI bleed

This RCT provides evidence that patients with acute UGIB have improved survival rates and fewer adverse events when a restrictive transfusion strategy is used. In addition to improving patient outcomes, a restrictive strategy will likely reduce costs and overall use of blood products. Thus, the study, along with other recent evaluations, adds evidence to support more restrictive transfusion thresholds.

The AABB (formerly named the American Association of Blood Banks) recently
released guidelines calling for restrictive transfusion thresholds (7-8 g/dL) in stable hospitalized patients.7 In 2012, the American College of Gastroenterology published a practice guideline with a recommended target hemoglobin level of ≥7 g/dL in the management of patients who have ulcer bleeding but no signs of intravascular depletion or comorbidities such as coronary artery disease.8

CAVEATS: Results might differ when endoscopy is delayed

The patients in the study detailed here underwent emergency gastroscopy within 6 hours of admission, and both groups received the same therapies based on endoscopic findings. It remains unclear whether the benefits of a restrictive transfusion strategy would persist in patients who do not undergo endoscopy within that timeframe. And, because the reported baseline characteristics of the patients did not include the prevalence of cardiac disease, caution should be exercised before extrapolating these results to patients with underlying (active or historical) cardiac disease.

CHALLENGES TO IMPLEMENTATION: Changing long-held policies may be difficult

Although RCTs as well as clinical guidelines suggest that restrictive transfusion policies are safe and effective, changing long-held clinical practices is never easy.

ACKNOWLEDGEMENT

The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Pages

Copyright 2013. The Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
File JFP06209e6_methodology41.21 KB

Recommended Reading

Expect miracles: New drug for hepatitis C may put treatment in the hands of primary care
MDedge Family Medicine
Pediatric-onset FAP increases persistent anxiety, depression risk
MDedge Family Medicine
Depression, some antidepressants linked to high C. difficile risk
MDedge Family Medicine
Preventing a second bout of acute pancreatitis
MDedge Family Medicine
Study identifies distinct microbiome in Crohn’s intestinal submucosa
MDedge Family Medicine
Interferon-free regimens effective for hepatitis C virus genotype 1
MDedge Family Medicine
Beware unpasteurized milk and milk products, expert says
MDedge Family Medicine
Colorectal cancer risk increased with bariatric surgery
MDedge Family Medicine
Vedolizumab shows promise in Crohn’s, ulcerative colitis
MDedge Family Medicine
Consensus statement: Data on cancer, pancreatitis do not warrant change in prescribing of antihyperglycemics
MDedge Family Medicine